Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V:
EVE; OTCQX: EEVVF) is pleased to announce that its wholly-owned
subsidiary, Natural MedCo Ltd. (“Natural MedCo”), has entered into
an exclusive letter of intent (the “LOI”) with ECS BioMed Inc.
(“Dr. Kerklaan Therapeutics”) effective January 14, 2020. The LOI
contemplates the exclusive right and license to manufacture, import
and export, warehouse, package, advertise, market, distribute and
sell the following products in Canada under the Dr. Kerklaan
Therapeutics brand, under the Eve & Co brand, or as co-branded
products under the Eve & Co and Dr. Kerklaan Therapeutics
brands: Natural CBD Relief Cream, Natural CBD Relief Stick, Natural
CBD Spray, Natural CBD Sleep Cream, Natural CBD Skin Cream, and
Natural CBD PMS Cream.
The LOI contemplates Natural MedCo and Dr.
Kerklaan Therapeutics entering into a licensing agreement by May
13, 2020. The term of the proposed license agreement is for an
initial five years commencing January 14, 2020, with Natural MedCo
having the option to extend the term in five year intervals. The
Company anticipates manufacturing and distributing CBD-infused
topicals to the Canadian market in 2020.
Melinda Rombouts, President and CEO of Eve &
Co commented, “We are very excited to be partnering with Dr.
Kerklaan Therapeutics on the development and distribution of CBD
Creams. Dr. Kerklaan and his team have brought their extensive
knowledge of the CBD industry and unparalleled enthusiasm to the
table, and we are eager to move forward together and capture the
potential for both companies in Canada.” Ms. Rombouts continued,
“Dr. Kerklaan has developed many high-end CBD topical products
which address a number of concerns and are a complementary fit for
our brand, Eve.”
“Canada represents an exciting opportunity for
Dr. Kerklaan Therapeutics. Expanding our international reach to
include Canada is an important milestone for the brand, and we’re
thrilled to have Eve & Co as a strategic partner to help launch
our collection of CBD topicals,” said Dr. Kerklaan, Founder &
CEO of Dr. Kerklaan Therapeutics.
Dr. Kerklaan Therapeutics hemp-based CBD
products have been featured in Vogue, The Oprah Magazine, Forbes,
Allure, Goop, Esquire and Rolling Stone magazines as well as other
publications as a leading CBD skincare product.
ABOUT EVE & CO INCORPORATED
Eve & Co, through its wholly-owned
subsidiary Natural MedCo Ltd., holds cultivation and processing
licences under the Cannabis Act (Canada) for the production and
sale of various cannabis products, including dried cannabis,
cannabis plants and extraction of cannabis oil. Natural MedCo Ltd.
was Canada’s first female-founded licensed producer of medicinal
marijuana and received its cultivation licence from Health Canada
in 2016. Eve & Co is led by a team of agricultural experts and
has a licensed 1,000,000 square foot greenhouse located in
Strathroy, Ontario.
The Company’s website can be visited at
www.evecannabis.ca.
ABOUT DR. KERKLAAN THERAPEUTICS
Dr. Kerklaan Therapeutics provides upscale,
highly effective plant-based CBD topical solutions. Dr. Kerklaan's
approach to designing CBD-infused health and wellness products
blends modern biochemistry with time-tested cannabidiol-based
remedies. Made with the highest quality ingredients, Dr. Kerklaan
Therapeutics’ combines premium essential oils with CBD hemp
extracts. All of Dr. Kerklaan Therapeutics products are rigorously
tested by independent third-party labs for quality and CBD
concentration certification and are made to the highest standards
of safety and efficacy. Dr. Kerklaan Therapeutics products are
distributed throughout the USA, UK and Europe.
Learn more at www.DrKerklaan.com
Neither the TSX Venture Exchange nor its
regulation services provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Notice regarding forward looking
statements:
Certain statements in this press release
constitute forward-looking information. All statements other than
statements of historical fact contained in this press release,
including, without limitation, those regarding the Company’s entry
into a definitive licensing agreement, expected timeline for the
manufacture, distribution and sale of cannabis-infused topicals,
expected timeline and licensing for the sale of classes of cannabis
under schedule 4 of the Cannabis Act, opportunities for growth,
future, strategy, plans, objectives, goals and targets, and any
statements preceded by, followed by or that include the words
“believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”,
“may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”,
“project”, “seek”, “should” or similar expressions or the negative
thereof, are forward-looking statements. These statements are not
historical facts but instead represent only the Company’s
expectations, estimates and projections regarding future events.
These statements are not guarantees of future performance and
involve assumptions, risks and uncertainties that are difficult to
predict, including those described in the Company’s management’s
discussion and analysis for the three and nine month periods ended
September 30, 2019 which is available on the Company’s SEDAR
profile. Therefore, actual results may differ materially from what
is expressed, implied or forecasted in such forward-looking
statements. The forward-looking information and forward-looking
statements included in this news release are made as of the date of
this news release. The Company does not undertake an obligation to
publicly update such forward-looking information or forward-looking
information to reflect new information, subsequent events or
otherwise unless required by applicable securities law.
For further information, please contact:
Melinda Rombouts President and Chief Executive Officer Eve &
Co Incorporated Telephone: (855) 628-6337
Landon Roedding Chief Financial Officer Eve & Co
Incorporated Telephone: (855) 628-6337
Jennifer Miller Communications Dr. Kerklaan Therapeutics
Telephone: (514) 476-1178
Eve & (TSXV:EVE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eve & (TSXV:EVE)
Historical Stock Chart
From Jul 2023 to Jul 2024